Invesaro

Stocks Comparison

Lantheus vs Intellia Therapeutics: revenue, profit, margins and growth compared

Lantheus brought in $1.5B of revenue in fiscal 2025, Intellia Therapeutics $67.7M in fiscal 2025. Revenue changed by +0.5% at Lantheus and +16.9% at Intellia Therapeutics on the year before, so Intellia Therapeutics grew faster. Lantheus kept 15.2% of its revenue as net profit, Intellia Therapeutics -609.9%. Free cash flow was $354.1M at Lantheus and -$395.9M at Intellia Therapeutics.

Side by side, latest fiscal year

LNTHNTLA
Fiscal year endedFY2025 (December 31, 2025)FY2025 (December 31, 2025)
Revenue$1.5B$67.7M
Revenue growth+0.5%+16.9%
Net income$233.6M-$412.7M
Net margin15.2%-609.9%
Free cash flow$354.1M-$395.9M
Free cash flow margin23.0%-585.0%
Earnings per share (diluted)$3.41-$3.81
Cash$359.1M$155.5M
Debt$738Kn/a
Price to earnings29.3n/a
Market value$6.5B$1.6B
Dividend yieldn/an/a
Rank by revenue in sector#118 of 523 · Health care#339 of 523 · Health care

Over the years

Revenue
LNTH FY2018: $343.4MLNTH FY2019: $347.3MLNTH FY2020: $339.4MLNTH FY2021: $425.2MLNTH FY2022: $935.1MLNTH FY2023: $1.3BLNTH FY2024: $1.5BLNTH FY2025: $1.5BNTLA FY2018: $30.4MNTLA FY2019: $43.1MNTLA FY2020: $58MNTLA FY2021: $33.1MNTLA FY2022: $52.1MNTLA FY2023: $36.3MNTLA FY2024: $57.9MNTLA FY2025: $67.7MFY18FY19FY20FY21FY22FY23FY24FY25
LNTH $1.5BNTLA $67.7M
Net income
LNTH FY2018: $40.5MLNTH FY2019: $31.7MLNTH FY2020: -$13.5MLNTH FY2021: -$71.3MLNTH FY2022: $28.1MLNTH FY2023: $326.7MLNTH FY2024: $312.4MLNTH FY2025: $233.6MNTLA FY2018: -$85.3MNTLA FY2019: -$474.2MNTLA FY2020: -$134.2MNTLA FY2021: -$267.9MNTLA FY2022: -$474.2MNTLA FY2023: -$481.2MNTLA FY2024: -$519MNTLA FY2025: -$412.7MFY18FY19FY20FY21FY22FY23FY24FY25
LNTH $233.6MNTLA -$412.7M
Net margin
LNTH FY2018: 11.8%LNTH FY2019: 9.1%LNTH FY2020: -4.0%LNTH FY2021: -16.8%LNTH FY2022: 3.0%LNTH FY2023: 25.2%LNTH FY2024: 20.4%LNTH FY2025: 15.2%NTLA FY2018: -280.4%NTLA FY2019: -1,100.1%NTLA FY2020: -231.5%NTLA FY2021: -810.5%NTLA FY2022: -909.8%NTLA FY2023: -1,326.5%NTLA FY2024: -896.8%NTLA FY2025: -609.9%FY18FY19FY20FY21FY22FY23FY24FY25
LNTH 15.2%NTLA -609.9%
Revenue growth
LNTH FY2019: +1.2%LNTH FY2020: -2.3%LNTH FY2021: +25.3%LNTH FY2022: +119.9%LNTH FY2023: +38.6%LNTH FY2024: +18.3%LNTH FY2025: +0.5%NTLA FY2019: +41.6%NTLA FY2020: +34.5%NTLA FY2021: -43.0%NTLA FY2022: +57.7%NTLA FY2023: -30.4%NTLA FY2024: +59.6%NTLA FY2025: +16.9%FY19FY20FY21FY22FY23FY24FY25
LNTH +0.5%NTLA +16.9%
Free cash flow
LNTH FY2018: $41.1MLNTH FY2019: $58.3MLNTH FY2020: $16.4MLNTH FY2021: $53.9MLNTH FY2022: $21.8MLNTH FY2023: $259.9MLNTH FY2024: $493.1MLNTH FY2025: $354.1MNTLA FY2018: -$67.6MNTLA FY2019: -$110MNTLA FY2020: -$53.5MNTLA FY2021: -$237.8MNTLA FY2022: -$346.8MNTLA FY2023: -$408.1MNTLA FY2024: -$354.7MNTLA FY2025: -$395.9MFY18FY19FY20FY21FY22FY23FY24FY25
LNTH $354.1MNTLA -$395.9M

Fiscal years as each company reports them; the two may end in different months.

Questions about Lantheus and Intellia Therapeutics

Which is bigger by revenue, Lantheus or Intellia Therapeutics?

Lantheus is bigger by revenue: $1.5B in fiscal 2025, against $67.7M for Intellia Therapeutics in fiscal 2025.

Which keeps more of its revenue as profit, Lantheus or Intellia Therapeutics?

Lantheus had a net margin of 15.2% in fiscal 2025; Intellia Therapeutics had -609.9% in fiscal 2025.

Which grew revenue faster, Lantheus or Intellia Therapeutics?

In their latest fiscal years revenue changed by +0.5% at Lantheus and +16.9% at Intellia Therapeutics.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies